// App-Quantinova.ai

: A real-world registry of patients with metastatic castration-resistant prostate cancer (mCRPC): REMPRO study.

Researchers

Presenter

  • Francisco Gonzalez

Principal Investigators

  • Rohit Kodagali

  • Teresa Tung

  • Mohamed Masoud

  • Viraj Rajadhyaksha

Medical Centers

  • AstraZeneca, Taipei, Taiwan

  • AstraZeneca, Bangalore, India

  • AstraZeneca, Macclesfield, United Kingdom

  • AstraZeneca Pharmaceuticals LP, Jeddah, Saudi Arabia

Locations

  • Saudi Arabia

  • India

  • United Kingdom

  • Taiwan

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Breast cancer type 2 susceptibility protein

Drug/Treatment

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Non Interventional

  • Multinational

  • Multicenteric

  • Cohort

Phase

  • NA

Study Id's

  • NCT04801186

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved